Lilly releases full phase 3 retatrutide data in obesity
The triple agonist's complete late-stage results set up competition with next-generation obesity candidates from rival developers.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 30 03:06 ETSource: Fierce Biotech
The wire
- 01Eli Lilly disclosed full phase 3 results for retatrutide, its GIP, GLP-1 and glucagon receptor triple agonist being developed for obesity.
- 02Clinicians and telehealth operators tracking the incretin pipeline will weigh retatrutide against tirzepatide and semaglutide on efficacy and tolerability.
- 03Regulatory filing timing, pricing and the full safety profile across the program remain the open questions for prescribers.
From the source
Read at fiercebiotech.comLilly sets up next-gen obesity battle with full phase 3 retatrutide data
